Clinical trials

  • JNJ-79635322 for Multiple myeloma
  • Valsartan; Sacubitril for Ischemic heart failure with mid-range ejection fraction (HFmrEF)
  • (S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-CYANO-4,4-DIFLUOROPYRROLIDIN-1-YL)-2-OXOETHYLCARBAMOYL)-QUINOLIN-6-YL)(METHYL)AMINO)-PROPYL)PIPERAZIN-1-YL)-2-OXOETHYL)-68GA-[1,4,7,10]-TETRAAZACYCLODODECANE-1,4,7-TRIYL)TRIACETATE for Idiopathic inflammatory myopathy|Crohn's disease|Ulcerative colitis|Fibrotic hypersensitivity pneumonitis|Idiopathic pulmonary fibrosis|Unclassifiable interstitial lung disease|Systemic sclerosis
  • Tetanus toxoid for Systemic sclerosis | Systemic lupus erythematosus | Rheumatoid arthritis
  • HUMANISED IGG1 LALAPS-YTE MONOCLONAL ANTIBODY AGAINST LYSOPHOSPHATIDIC ACID RECEPTOR 1 for Idiopathic pulmonary fibrosis
  • LTG-001 for Osteoarthritis of the knee
  • ARSENIC TRIOXIDE for Myelodysplastic syndromes | Low-risk myelodysplastic syndrome
  • empagliflozin for Hypertrophic cardiomyopathy
  • SUGAMMADEX SODIUM for General anesthesia
  • AMOXICILLIN SODIUM for Erysipelas (lower limb)
  • LEUPRORELIN ACETATE for Prostate adenocarcinoma (high risk of recurrence)
  • BENZYLPENICILLIN PROCAINE, BENZATHINE BENZYLPENICILLIN, BENZYLPENICILLIN POTASSIUM for Serious bacterial infections in critically ill patients